Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.

Faced with unsatisfactory results of treatment for advanced Hodgkin's disease, we investigated three combinations of chemotherapy. From 1993 to 1998, 1201 eligible patients 15 to 65 years of age who had newly diagnosed Hodgkin's disease in unfavorable stage IIB or IIIA or stage IIIB or IV were randomly assigned to receive eight cycles of cyclophosphamide, vincristine, procarbazine, and prednisone alternating with doxorubicin, bleomycin, vinblastine, and dacarbazine (COPP-ABVD); bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP); or increased-dose BEACOPP, each followed by local radiotherapy when indicated. Enrollment in the COPP-ABVD group was stopped in 1996 owing to inferior results. For the final analysis, 1195 of 1201 patients could be evaluated: 260 in the COPP-ABVD group, 469 in the BEACOPP group, and 466 in the increased-dose BEACOPP group; the median follow-up was 72, 54, and 51 months, respectively. The rate of freedom from treatment failure at five years was 69 percent in the COPP-ABVD group, 76 percent in the BEACOPP group, and 87 percent in the increased-dose BEACOPP group (P=0.04 for the comparison of the COPP-ABVD group with the BEACOPP group and P<0.001 for the comparison of the increased-dose BEACOPP group with the COPP-ABVD group and with the BEACOPP group), and the five-year rates of overall survival were 83 percent, 88 percent, and 91 percent, respectively (P=0.16 for the comparison of the COPP-ABVD group with the BEACOPP group, P=0.06 for the comparison of the BEACOPP group with the increased-dose BEACOPP group, and P=0.002 for the comparison of the COPP-ABVD group with the increased-dose BEACOPP group). Rates of early progression were significantly lower with increased-dose BEACOPP than with COPP-ABVD or standard BEACOPP. Increased-dose BEACOPP resulted in better tumor control and overall survival than did COPP-ABVD.

Diehl V ，Franklin J ，Pfreundschuh M ，Lathan B ，Paulus U ，Hasenclever D ，Tesch H ，Herrmann R ，Dörken B ，Müller-Hermelink HK ，Dühmke E ，Loeffler M ，German Hodgkin's Lymphoma Study Group ... -  《-》

Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.

Engert A ，Diehl V ，Franklin J ，Lohri A ，Dörken B ，Ludwig WD ，Koch P ，Hänel M ，Pfreundschuh M ，Wilhelm M ，Trümper L ，Aulitzky WE ，Bentz M ，Rummel M ，Sezer O ，Müller-Hermelink HK ，Hasenclever D ，Löffler M ... -  《-》

Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.

Eich HT ，Diehl V ，Görgen H ，Pabst T ，Markova J ，Debus J ，Ho A ，Dörken B ，Rank A ，Grosu AL ，Wiegel T ，Karstens JH ，Greil R ，Willich N ，Schmidberger H ，Döhner H ，Borchmann P ，Müller-Hermelink HK ，Müller RP ，Engert A ... -  《-》

BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.

Diehl V ，Franklin J ，Hasenclever D ，Tesch H ，Pfreundschuh M ，Lathan B ，Paulus U ，Sieber M ，Rueffer JU ，Sextro M ，Engert A ，Wolf J ，Hermann R ，Holmer L ，Stappert-Jahn U ，Winnerlein-Trump E ，Wulf G ，Krause S ，Glunz A ，von Kalle K ，Bischoff H ，Haedicke C ，Duehmke E ，Georgii A ，Loeffler M ... -  《JOURNAL OF CLINICAL ONCOLOGY》

ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

Viviani S ，Zinzani PL ，Rambaldi A ，Brusamolino E ，Levis A ，Bonfante V ，Vitolo U ，Pulsoni A ，Liberati AM ，Specchia G ，Valagussa P ，Rossi A ，Zaja F ，Pogliani EM ，Pregno P ，Gotti M ，Gallamini A ，Rota Scalabrini D ，Bonadonna G ，Gianni AM ，Michelangelo Foundation ，Gruppo Italiano di Terapie Innovative nei Linfomi ，Intergruppo Italiano Linfomi ... -  《-》